Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: A pilot study

Epilepsy and Behavior

Volumn 29, Issue 1, 2013, Pages 150-154

  Asadi Pooya, Ali A ^a,b   Razavizadegan, S Mohammad Ali ^a   Abdi Ardekani, Alireza ^a   Sperling, Michael R ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

P gp inhibitor; Seizure reduction; Temporal lobe epilepsy; Verapamil

Indexed keywords

VERAPAMIL;

ADULT; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; MALE; MEDICATION COMPLIANCE; NAUSEA; OPEN STUDY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE; VERTIGO;

P-GP INHIBITOR; SEIZURE REDUCTION; TEMPORAL LOBE EPILEPSY; VERAPAMIL;

ADOLESCENT; ADULT; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY, TEMPORAL LOBE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; VERAPAMIL; YOUNG ADULT;

EID: 84882960860     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.07.006     Document Type: Article

References (27)

1. Ryvlin P. The modern challenges of drug resistant epilepsy. Epileptic Disord 2005, 7(Suppl. 1):S1-S2.
2. Asadi-Pooya A.A., Emami M., Ashjazadeh N., Nikseresht A., Shariat A., Petramfar P., et al. Reasons for uncontrolled seizures in adults; the impact of pseudointractability. Seizure 2013, [pii: S1059-1311(13)00011-3]. 10.1016/j.seizure.2013.01.010.
3. Asadi-Pooya A.A., Emami M. Reasons for uncontrolled seizures in children; the impact of pseudointractability. Epilepsy Behav 2012, 25(3):341-344.
4. Beyenburg S., Bauer J., Reuber M. New drugs for the treatment of epilepsy: a practical approach. Postgrad Med J 2004, 80:581-587.
5. Nei M., O'Connor M., Liporace J., Sperling M.R. Refractory generalized seizures: response to corpus callosotomy and vagal nerve stimulation. Epilepsia 2006, 47(1):115-122.
6. Schmidt D., Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46(6):858-877.
7. Loscher W. Mechanisms of drug resistance. Epileptic Disord 2005, 7(Suppl. 1):S3-S9.
8. Tishler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., Raffel C. MDR 1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995, 36:1-6.
9. Marchi N., Hallene K.L., Kight K.M., Cucullo L., Moddel G., Bingaman W., et al. Significance of MDR 1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2004, 2:37.
10. Volk H.A., Burkhardt K., Potschka H., Chen J., Becker A., Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004, 123:751-759.
11. Sisodiya S.M., Lin W.R., Harding B.N., Squier M.V., Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125:22-31.
12. Summers M.A., Moore J.L., McAuley J.W. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004, 38:1631-1634.
13. Loscher W. How to explain multidrug resistance in epilepsy?. Epil Current 2005, 5(3):107-112.
14. AHFS drug information 2006, 1890-1898.
15. Wisner K.L., Peindl K.S., Perel J.M., Hanusa B.H., Piontek C.M., Baab S. Verapamil treatment for women with bipolar disorder. Biol Psychiatry 2002, 51:745-752.
16. Hollister L.E., Trevino E.S.G. Calcium channel blockers in psychiatric disorders: a review of the literature. Can J Psychiatry 1999, 44:658-664.
17. Pringsheim T., Davenport W., Mackie G., Worthington I., Aubé M., Christie S.N., et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 2012, 39(2 Suppl. 2):S1-S59.
18. Potschka H., Baltes S., Loscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 2004, 58:85-91.
19. Krauss G.L., Serratosa J.M., Villanueva V., Endziniene M., Hong Z., French J., et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012, 78(18):1408-1415.
20. Porter R.J., Partiot A., Sachdeo R., Nohria V., Alves W.M., 205 Study Group Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007, 68(15):1197-1204.
21. Pellock J.M., Carman W.J., Thyagarajan V., Daniels T., Morris D.L., D'Cruz O. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology 2012, 79(14):1482-1489.
22. Anhut H., Ashman P., Feuerstein T.J., Sauermann W., Saunders M., Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994, 35(4):795-801.
23. Ben-Menachem E., Gabbai A.A., Hufnagel A., Maia J., Almeida L., Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 2010, 89(2-3):278-285.
24. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006, 69:273-294.
25. Schmidt D. Efficacy of new antiepileptic drugs. Epilepsy Curr 2011, 11:9-11.
26. Asadi-Pooya A.A., Sperling M.R. Potentiation of antiepileptic drugs effectiveness by pyronaridine in refractory epilepsy. Med Hypotheses 2007, 69(3):560-563.
27. Michelson E.L. Calcium antagonists in cardiology: update on sustained-release delivery systems. Clin Cardiol 1991, 14:947-950.